Postinduction dexamethasone and individualized dosing of escherichia coli l-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study - Dana-Farber Cancer Institute ALL Consortium Protocol 00-01

Journal of Clinical Oncology

Volumn 31, Issue 9, 2013, Pages 1202-1210

  Vrooman, Lynda M ^a,b   Stevenson, Kristen E ^a   Supko, Jeffrey G ^c   O'Brien, Jane ^a   Dahlberg, Suzanne E ^a   Asselin, Barbara L ^e   Athale, Uma H ^l   Clavell, Luis A ^g   Kelly, Kara M ^f   Kutok, Jeffery L ^d   Laverdière, Caroline ^m   Lipshultz, Steven E ^h   Michon, Bruno ⁿ   Schorin, Marshall ⁱ   Relling, Mary V ^j   Cohen, Harvey J ^k   Neuberg, Donna S ^a   Sallan, Stephen E ^a,b   Silverman, Lewis B ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Infinity Pharmaceuticals Inc   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g San Jorge Children's Hospital   (Puerto Rico)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ INOVA FAIRFAX HOSPITAL FOR CHILDREN   (United States)

^j ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l MCMASTER UNIVERSITY   (Canada)

^m UNIVERSITY OF MONTREAL   (Canada)

ⁿ LAVAL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RAZOXANE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BEDTIME DOSAGE; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; FRACTURE; HIGH RISK POPULATION; HUMAN; INDUCTION CHEMOTHERAPY; INFANT; INFECTION; INFECTION RATE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL RATE;

ADOLESCENT; ANTINEOPLASTIC AGENTS, HORMONAL; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ESCHERICHIA COLI; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; INFANT; INFECTION; MALE; MONITORING, PHYSIOLOGIC; MULTIVARIATE ANALYSIS; OSTEONECROSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 84875246943     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.2070     Document Type: Article

References (33)

1. Jones B, Freeman AI, Shuster JJ, et al: Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19:269-275, 1991
2. Gaynon PS, Lustig RH: The use of glucocorticoids in acute lymphoblastic leukemia of childhood: Molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol 17:1-12, 1995
3. Bostrom BC, Sensel MR, Sather HN, et al: Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 101:3809-3817, 2003 (Pubitemid 36857851)
4. Mitchell CD, Richards SM, Kinsey SE, et al: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: Results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129:734-745, 2005 (Pubitemid 40904523)
5. Igarashi S, Manabe A, Ohara A, et al: No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol 23:6489-6498, 2005 (Pubitemid 46190240)
6. De Moerloose B, Suciu S, Bertrand Y, et al: Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): Report of the EORTC randomized phase 3 trial 58951. Blood 116:36-44, 2010
7. Strauss AJ, Su JT, Dalton VM, et al: Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol 19:3066-3072, 2001 (Pubitemid 32565445)
8. Silverman LB, Gelber RD, Dalton VK, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 97:1211-1218, 2001 (Pubitemid 32183741)
9. Ahlke E, Nowak-Göttl U, Schulze-Westhoff P, et al: Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 96:675-681, 1997 (Pubitemid 27115859)
10. Avramis VI, Sencer S, Periclou AP, et al: A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 99:1986-1994, 2002 (Pubitemid 34525479)
11. Berg SL, Balis FM, McCully CL, et al: Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey. Cancer Chemother Pharmacol 32:310-314, 1993 (Pubitemid 23172090)
12. Boos J, Werber G, Ahlke E, et al: Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 32A:1544-1550, 1996 (Pubitemid 26279122)
13. Riccardi R, Holcenberg JS, Glaubiger DL, et al: L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 41:4554-4558, 1981 (Pubitemid 12201374)
14. Rizzari C, Zucchetti M, Conter V, et al: L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C or E coli L-asparaginase as first exposure. Ann Oncol 11:189-193, 2000 (Pubitemid 30148733)
15. Avramis VI, Panosyan EH: Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future. Clin Pharmacokinet 44:367-393, 2005 (Pubitemid 40663683)
16. Vrooman LM, Supko JG, Neuberg DS, et al: Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 54:199-205, 2010
17. Silverman LB, McLean TW, Gelber RD, et al: Intensified therapy for infants with acute lymphoblastic leukemia: Results from the Dana-Farber Cancer Institute Consortium. Cancer 80:2285-2295, 1997 (Pubitemid 28007400)
18. Silverman LB, Gelber RD, Young ML, et al: Induction failure in acute lymphoblastic leukemia of childhood. Cancer 85:1395-1404, 1999 (Pubitemid 29125096)
19. Moghrabi A, Levy DE, Asselin B, et al: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109:896-904, 2007 (Pubitemid 46220632)
20. Kawedia JD, Liu C, Pei D, et al: Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 119:1658-1664, 2012
21. Liu C, Kawedia JD, Cheng C, et al: Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 26:2303-2309, 2012
22. Zhou J, Goldwasser MA, Li A, et al: Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 110:1607-1611, 2007 (Pubitemid 47443978)
23. Evans WE, Relling MV, Rodman JH, et al: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998 (Pubitemid 28103133)
24. Willer A, Gerss J, König T, et al: Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: A retrospective analysis within the ALL-BFM trials. Blood 118:5774-5782, 2011
25. Mattano LA Jr, Sather HN, Trigg ME, et al: Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group. J Clin Oncol 18:3262-3272, 2000
26. Werner A, Jäger M, Schmitz H, et al: Joint preserving surgery for osteonecrosis and osteochondral defects after chemotherapy in childhood. Klin Padiatr 215:332-337, 2003 (Pubitemid 38064632)
27. Davies JH, Evans BA, Jenney ME, et al: Skeletal morbidity in childhood acute lymphoblastic leukaemia. Clin Endocrinol (Oxf) 63:1-9, 2005 (Pubitemid 40966395)
28. Bürger B, Beier R, Zimmermann M, et al: Osteonecrosis: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL) - Experiences from trial ALL-BFM 95. Pediatr Blood Cancer 44:220-225, 2005 (Pubitemid 40209430)
29. Patel B, Richards SM, Rowe JM, et al: High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: A UKALL XII analysis. Leukemia 22:308-312, 2008 (Pubitemid 351250536)
30. Pui CH, Campana D, Pei D, et al: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730-2741, 2009
31. Kawedia JD, Kaste SC, Pei D, et al: Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 117:2340-2347, 2011
32. Hurwitz CA, Silverman LB, Schorin MA, et al: Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 88:1964-1969, 2000 (Pubitemid 30213008)
33. Belgaumi AF, Al-Bakrah M, Al-Mahr M, et al: Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer 97:2898-2903, 2003 (Pubitemid 36605160)